Drug sales for major depressive disorders (MDD) in the US are expected to grow at a compound annual growth rate (CAGR) of 6.6% to reach $4.6bn by 2025, compared to $2.4bn in 2015, according to a report by GlobalData.

Titled 'PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025', the report states attributes the growth to the availability of a wide range of treatments and the commercial success of atypical antipsychotics.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The same factors will help the country to remain the biggest major market for MDD drugs, adds the report.

Antipsychotics accounted for 39% of the MDD drug sales in the US in 2015 and their sales are expected to grow at a CAGR of 7.1% to reach $1.9bn in sales by the end of the forecast period, retaining their market share.

"The pipeline drugs are forecast to generate combined sales of more than $800m, led by Janssen’s esketamine, by 2025."

Drugs in the class are currently priced high, resulting in increasing sales of generic aripiprazole.

See Also:

Abilify was the most-sold atypical antipsychotic in 2015 and its sales are expected to remain flat during the forecast period, due to competition from generics and Otsuka / Lundbeck’s Rexulti.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The report further mentions five MDD drugs that are currently in late-stage pipeline and will enter the US market, which include Alkermes’ ALKS-5461, Allergan / Gedeon Richter / Mitsubishi Tanabe’s Vraylar, Axsome Therapeutics’ AXS-05, Janssen’s esketamine, and Allergan’s rapastinel.

The pipeline drugs are forecast to generate combined sales of more than $800m, led by Janssen’s esketamine, by 2025.